pharmaphorum

JULY 14, 2021

The bulk of Prevnar 13 sales come from use in adults, and with Merck & Co in the final stages of regulatory review of its rival vaccine V114 – covering 15 serotypes and filed for adult use – the franchise is facing some serious competition for the first time. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

pharmaphorum

MAY 31, 2022

billion in sales last year. The pandemic and the timing of US government purchases for immunisation campaigns trimmed back sales from almost $5.9 The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot.

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

The Pharma Data

JUNE 2, 2022

” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. New GSK reaffirms its full-year 2022 guidance and the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

MAY 31, 2022

In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. New GSK reaffirms its full-year 2022 guidance and the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52